Tamar natural gas estimates up 16%

By RON FRIEDMAN
September 8, 2009 10:25
2 minute read.
A natural gas pipeline [illustrative].

A natural gas pipeline [illustrative].. (photo credit: Courtesy)

The recently discovered Tamar natural gas well, off the coast of Israel, is projected to contain 16 percent more natural gas than early estimates predicted.


According to an announcement issued by Noble Energy, Inc. on Tuesday, reserves are estimated at 207 billion cubic meters instead of the previously estimated 178.



Be the first to know - Join our Facebook page.


In an announcement to the Tel Aviv Stock Exchange, American energy giant Noble Energy, which owns 36% of the gas field and operates the site on behalf of a group of companies, notified its partners and the public about the findings, which where compiled by Netherland, Sewell and Associates, Inc., a Texas-based petroleum consultancy company.



Other interest owners in the well are Isramco Negev 2 with 28.75%, Delek Drilling with 15.625%, Avner Oil Exploration with 15.625% and Dor Gas Exploration with the remaining 4%.



The new estimate brings Tamar's proven and probable reserves to 218 billion cubic meters. The proven and probable reserves are the basis for the partnership's development plans. The partner's shares rose as a result of the announcement.



Gideon Tadmor, CEO of Avner, and Tzvi Greenfeld, CEO of Delek, said, "The professional and independent report that was received verifies the remarkable size and quality of the Tamar Field."





The two said that recent gas findings at Tamar and Dalit are strategic assets to the State of Israel and its energy market and releases it from dependency on foreign elements.



"There is already enough Israeli-made natural gas to provide the country's needs for years to come, and we plan to determinedly seek out additional reserves in our many licenses along the coast of Israel," said the two in a press release.



Yitzhak Tshuva of Delek Group told Israel Radio that the discovery could provide Israel's gas needs for the next 20 to 25 years.



Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS